Eli Lilly Dirección

Dirección controles de criterios 2/4

El CEO de Eli Lilly's es Dave Ricks , nombrado en Jan 2017, tiene una permanencia de 7.25 años. compensación anual total es $26.57M, compuesta por 6.1% salario y 93.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.076% de las acciones de la empresa, por valor de $502.57M. La antigüedad media del equipo directivo y de la junta directiva es de 5.8 años y 9.4 años, respectivamente.

Información clave

Dave Ricks

Chief Executive Officer (CEO)

US$26.6m

Compensación total

Porcentaje del salario del CEO	6.1%
Permanencia del CEO	7.3yrs
Participación del CEO	0.08%
Permanencia media de la dirección	5.8yrs
Promedio de permanencia en la Junta Directiva	9.4yrs

Actualizaciones recientes de la dirección

Recent updates

Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value

Jan 31

Eli Lilly (NYSE:LLY) Has Announced That It Will Be Increasing Its Dividend To $1.30

Jan 24

Eli Lilly: The Cupboard Is Fully Stocked

Jan 19

Eli Lilly: The Buzz Is Not Over

Jan 11

Eli Lilly (NYSE:LLY) Is Increasing Its Dividend To $1.30

Jan 10

Eli Lilly (NYSE:LLY) Is Paying Out A Larger Dividend Than Last Year

Dec 27

Pinning Down Eli Lilly and Company's (NYSE:LLY) P/S Is Difficult Right Now

Dec 24

Eli Lilly: Long Path To A Trillion

Dec 21

Eli Lilly (NYSE:LLY) Has A Pretty Healthy Balance Sheet

Dec 05

Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly

Nov 30

Eli Lilly: Perfectly Priced Healthcare Giant

Nov 16

Eli Lilly: Zepbound For Weight Loss FDA Approved - Time To Believe The Hype?

Nov 09

Calculating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)

Oct 30

Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated

Oct 11

Eli Lilly: Big Cancer Bet With Point Biopharma Global Purchase

Oct 05

Eli Lilly: Don't Be Fooled By Greed

Sep 20

Eli Lilly Stock Hits New All-Time Highs: Is It Still A Buy?

Sep 11

Here's Why We Think Eli Lilly (NYSE:LLY) Is Well Worth Watching

Sep 11

Is Eli Lilly (NYSE:LLY) Using Too Much Debt?

Aug 24

Sell Eli Lilly And Buy This Coiled-Spring Dividend Aristocrat Instead

Aug 23

Eli Lilly Q2: Dividends Don't Lie

Aug 14

Eli Lilly Remains A Buy With Strong Sales And Possible Upside With Mounjaro

Aug 08

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Dave Ricks en comparación con los beneficios de Eli Lilly?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$27m	US$2m	US$5b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$21m	US$2m	US$6b
Sep 30 2022	n/a	n/a	US$6b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$22m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$24m	US$1m	US$6b
Sep 30 2020	n/a	n/a	US$6b
Jun 30 2020	n/a	n/a	US$6b
Mar 31 2020	n/a	n/a	US$6b
Dec 31 2019	US$21m	US$1m	US$5b
Sep 30 2019	n/a	n/a	US$4b
Jun 30 2019	n/a	n/a	US$4b
Mar 31 2019	n/a	n/a	US$3b
Dec 31 2018	US$17m	US$1m	US$3b
Sep 30 2018	n/a	n/a	US$372m
Jun 30 2018	n/a	n/a	-US$166m
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$16m	US$1m	-US$86m

Compensación vs. Mercado: La compensación total de Dave($USD26.57M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD13.51M).

Compensación vs. Ingresos: La compensación de Dave ha aumentado más de un 20%, mientras que los beneficios de la empresa han caído más de un 20% en el último año.

CEO

Dave Ricks (55 yo)

7.3yrs

Permanencia

US$26,565,732

Compensación

Mr. David A. Ricks, also known as Dave, has been a Director of Adobe Inc. since April 12, 2018 and previously served as its Director since June 2017. He served as a Director of Elanco Animal Health Incorpo...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
David Ricks	Chairman	7.3yrs	US$26.57m	0.076% $ 504.1m
Anat Ashkenazi	Executive VP & CFO	3.2yrs	US$7.60m	0.0047% $ 31.2m
Daniel Skovronsky	EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology	5.8yrs	US$11.85m	0.022% $ 142.1m
Anat Hakim	Executive VP	4.2yrs	US$7.01m	0.0034% $ 22.3m
Jacob Van Naarden	Executive VP & President of Loxo	no data	US$4.89m	0.0023% $ 15.0m
Donald Zakrowski	Senior VP of Finance & Chief Accounting Officer	11.4yrs	sin datos	0.0011% $ 7.0m
Diogo Rau	EVP & Chief Information and Digital Officer	2.9yrs	US$5.10m	0.00087% $ 5.7m
Alonzo Weems	EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer	2.8yrs	sin datos	0.00088% $ 5.8m
Eric Dozier	Executive Vice President of Human Resources & Diversity	1.3yrs	sin datos	0.00083% $ 5.5m
Jeffrey Simmons	Senior VP & President of Elanco Animal Health	16.3yrs	US$5.38m	sin datos
W. Moody	SVP of Global Active Pharmaceutical Ingredient	7.7yrs	sin datos	sin datos
Johna Norton	Executive Vice President of Global Quality	7yrs	sin datos	0.0039% $ 25.5m

5.8yrs

Permanencia media

52.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de LLY es experimentado (5.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
David Ricks	Chairman	7.3yrs	US$26.57m	0.076% $ 504.1m
Gabrielle Greene-Sulzberger	Independent Director	3.3yrs	US$335.50k	0.00024% $ 1.6m
Sidney Taurel	Chairman Emeritus	15.3yrs	US$13.06m	sin datos
Jon Erik Fyrwald	Independent Director	18.4yrs	US$344.88k	0.000010% $ 66.1k
Ralph Alvarez	Independent Director	15yrs	US$336.00k	0.000080% $ 528.6k
William Kaelin	Independent Director	11.8yrs	US$349.15k	sin datos
Juan Luciano	Lead Independent Director	8.2yrs	US$373.00k	0.0017% $ 11.5m
Katherine Baicker	Independent Director	12.3yrs	US$336.00k	sin datos
Jamere Jackson	Independent Director	7.5yrs	US$345.00k	sin datos
Marschall Runge	Independent Director	10.6yrs	US$319.00k	0.000020% $ 132.1k
Karen Walker	Independent Director	5.3yrs	US$359.00k	sin datos
Kimberly Johnson	Independent Director	3.2yrs	US$316.00k	0.00029% $ 1.9m

9.4yrs

Permanencia media

62.5yo

Promedio de edad

Junta con experiencia: La junta directiva de LLY se considera experimentada (9.4 años de antigüedad promedio).

Eli Lilly Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Philip Johnson to Retire as Eli Lilly and Company's Treasurer

Chairman exercised options and sold US$8.5m worth of stock

Insufficient new directors

Johna Norton to Retire as Lilly Executive Vice President of Global Quality

Insider exercised options and sold US$1.3m worth of stock

Recent updates

What You Can Learn From Eli Lilly and Company's (NYSE:LLY) P/S

Eli Lilly and Company to Report Q1, 2024 Results on Apr 30, 2024

Wall Street Lunch: Lilly In Limelight

As You Sow Files an Exempt Solicitation Statement and Request Vote for the Proposal

Eli Lilly: Diabetes And Weight Management Treatments Are The Winning Tickets

SEIU Benefit Plans Master Trust Files a Notice of Exempt Solicitation to Eli Lilly and Company

Eli Lilly: The Party Is Not Over

Estimating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company Announces Results from A First-Of-Its-Kind Study of Lebrikizumab

Eli Lilly and Company to Present Donanemab in Early Symptomatic Alzheimer's Disease

New major risk - Financial position

Eli Lilly: Yes, It Is Too Late To Join The Party

Eli Lilly: Overvaluation Is A Big Red Flag

Philip Johnson to Retire as Eli Lilly and Company's Treasurer

Eli Lilly and Company: Even 'Miracle Drugs' Can't Keep Stock Rising (Downgrade)

Price target increased by 11% to US$705

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of US$1.30 per share at 0.7% yield

Eli Lilly and Company Provides Earnings Guidance for the Fiscal Year 2024

Chairman exercised options and sold US$8.5m worth of stock

Insufficient new directors

Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value

Johna Norton to Retire as Lilly Executive Vice President of Global Quality

Eli Lilly and Company to Report Q4, 2023 Results on Feb 06, 2024

Eli Lilly (NYSE:LLY) Has Announced That It Will Be Increasing Its Dividend To $1.30

Eli Lilly: The Cupboard Is Fully Stocked

Eli Lilly: The Buzz Is Not Over

Eli Lilly (NYSE:LLY) Is Increasing Its Dividend To $1.30

Eli Lilly and Company Launches End-To-End Digital Healthcare Experience Through LillyDirect

Eli Lilly and Company (NYSE:LLY) completed the acquisition of POINT Biopharma Global Inc. (NasdaqCM:PNT) from Joe A. McCann, Allan Charles Silber, Neil E. Fleshner and others.

Eli Lilly (NYSE:LLY) Is Paying Out A Larger Dividend Than Last Year

Pinning Down Eli Lilly and Company's (NYSE:LLY) P/S Is Difficult Right Now

Eli Lilly: Long Path To A Trillion

Eli Lilly and Company Announces Updated Clinical Data from the International Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Eli Lilly and Company Declares Dividend for the First Quarter of 2024, Payable on March 8, 2024

Insider exercised options and sold US$1.3m worth of stock

Eli Lilly and Company Announces Availability of Zepbound (Tirzepatide) Injection

Eli Lilly (NYSE:LLY) Has A Pretty Healthy Balance Sheet

Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Jaypirca (Pirtobrutinib) for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphocytic Lymphoma

Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly

Eli Lilly: Perfectly Priced Healthcare Giant

Eli Lilly: Zepbound For Weight Loss FDA Approved - Time To Believe The Hype?

U.S. Food and Drug Administration Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems

Upcoming dividend of US$1.13 per share at 0.8% yield

New minor risk - Earnings quality

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Eli Lilly and Company Revises Earnings Guidance for the Year 2023

Consensus EPS estimates fall by 26%

Calculating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company Announces FDA Approval for Omvoh (Mirikizumab-Mrkz) Infusion (300 mg/15 mL)/Injection (100 mg/mL)

Lilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer

Eli Lilly and Company to Report Q3, 2023 Results on Nov 02, 2023

Eli Lilly and Company (NYSE:LLY) signed an agreement to acquire Mablink Bioscience S.A.S.

Eli Lilly and Company (NYSE:LLY) signed an agreement to acquire Mablink Bioscience S.A.S.

Consensus EPS estimates fall by 10%

Eli Lilly and Company Announces Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 Trial

Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire POINT Biopharma Global Inc. (NasdaqCM:PNT) from Joe A. McCann, Allan Charles Silber, Neil E. Fleshner and others for approximately $1.4 billion.

Eli Lilly: Big Cancer Bet With Point Biopharma Global Purchase

U.S. Food and Drug Administration Issues Complete Response Letter for Lebrikizumab Based on Inspection Findings At Third-Party Manufacturer

Boehringer Ingelheim and Eli Lilly and Company Announce US FDA Approves Jardiance for Treatment of Adults with Chronic Kidney Disease

Eli Lilly: Don't Be Fooled By Greed

Eli Lilly Stock Hits New All-Time Highs: Is It Still A Buy?

Here's Why We Think Eli Lilly (NYSE:LLY) Is Well Worth Watching

Is Eli Lilly (NYSE:LLY) Using Too Much Debt?

Eli Lilly and Company Announces Topline Results from the Libretto-531 Study Evaluating Retevmo

Sell Eli Lilly And Buy This Coiled-Spring Dividend Aristocrat Instead

Eli Lilly and Company (NYSE:LLY) acquired Versanis Bio, Inc. from Medicxi Ventures (UK) LLP and others.

Consensus EPS estimates increase by 13%

Investor sentiment improves as stock rises 18%